Autologous stem cell transplantation after complete remission and first consolidation in acute myeloid leukemia patients aged 61-70 years: results of the prospective EORTC-GIMEMA AML-13 study

X Thomas; S Suciu; B Rio; Giuseppe Leone; G Broccia; G Fillet; U Jehn; W Feremans; G Meloni; M Vignetti; T De Witte; S. Amadori

Autologous stem cell transplantation after complete remission and first consolidation in acute myeloid leukemia patients aged 61-70 years: results of the prospective EORTC-GIMEMA AML-13 study

X Thomas, S Suciu, B Rio, Giuseppe Leone, G Broccia, G Fillet, U Jehn, W Feremans, G Meloni, M Vignetti, T De Witte, S. Amadori

Research output: Contribution to journal › Article

33 Citations (Scopus)

Abstract

The optimal post-remission treatment for elderly patients with acute myeloid leukemia (AML) is presently unknown. Recent studies have reported the feasibility of autologous peripheral blood stem cell transplantation (PBSCT) in this population. We evaluate the outcome of this post-remission approach after complete remission (CR) and consolidation in elderly patients included in the EORTC-GIMEMA AML-13 trial.

Original language	English
Pages (from-to)	389-396
Number of pages	8
Journal	Haematologica
Volume	92
Publication status	Published - 2007
Externally published	Yes

Keywords

Administration, Oral
Aged
Aged, 80 and over
Amsacrine
Antineoplastic Combined Chemotherapy Protocols
Carmustine
Combined Modality Therapy
Cytarabine
Disease-Free Survival
Etoposide
Feasibility Studies
Female
Graft Survival
Granulocyte Colony-Stimulating Factor
Hematopoietic Stem Cell Transplantation
Humans
Idarubicin
Infusions, Intravenous
Injections, Subcutaneous
Kaplan-Meier Estimate
Leukemia, Myeloid
Male
Middle Aged
Peripheral Blood Stem Cell Transplantation
Prospective Studies
Recombinant Proteins
Survival Analysis
Transplantation Conditioning
Transplantation, Autologous
Treatment Outcome

Cite this

Thomas, X., Suciu, S., Rio, B., Leone, G., Broccia, G., Fillet, G., Jehn, U., Feremans, W., Meloni, G., Vignetti, M., De Witte, T., & Amadori, S. (2007). Autologous stem cell transplantation after complete remission and first consolidation in acute myeloid leukemia patients aged 61-70 years: results of the prospective EORTC-GIMEMA AML-13 study. Haematologica, 92, 389-396.

@article{2b1f39fad44f47948dfdc402b4861249,

title = "Autologous stem cell transplantation after complete remission and first consolidation in acute myeloid leukemia patients aged 61-70 years: results of the prospective EORTC-GIMEMA AML-13 study",

abstract = "The optimal post-remission treatment for elderly patients with acute myeloid leukemia (AML) is presently unknown. Recent studies have reported the feasibility of autologous peripheral blood stem cell transplantation (PBSCT) in this population. We evaluate the outcome of this post-remission approach after complete remission (CR) and consolidation in elderly patients included in the EORTC-GIMEMA AML-13 trial.",

keywords = "Administration, Oral, Aged, Aged, 80 and over, Amsacrine, Antineoplastic Combined Chemotherapy Protocols, Carmustine, Combined Modality Therapy, Cytarabine, Disease-Free Survival, Etoposide, Feasibility Studies, Female, Graft Survival, Granulocyte Colony-Stimulating Factor, Hematopoietic Stem Cell Transplantation, Humans, Idarubicin, Infusions, Intravenous, Injections, Subcutaneous, Kaplan-Meier Estimate, Leukemia, Myeloid, Male, Middle Aged, Peripheral Blood Stem Cell Transplantation, Prospective Studies, Recombinant Proteins, Survival Analysis, Transplantation Conditioning, Transplantation, Autologous, Treatment Outcome, Administration, Oral, Aged, Aged, 80 and over, Amsacrine, Antineoplastic Combined Chemotherapy Protocols, Carmustine, Combined Modality Therapy, Cytarabine, Disease-Free Survival, Etoposide, Feasibility Studies, Female, Graft Survival, Granulocyte Colony-Stimulating Factor, Hematopoietic Stem Cell Transplantation, Humans, Idarubicin, Infusions, Intravenous, Injections, Subcutaneous, Kaplan-Meier Estimate, Leukemia, Myeloid, Male, Middle Aged, Peripheral Blood Stem Cell Transplantation, Prospective Studies, Recombinant Proteins, Survival Analysis, Transplantation Conditioning, Transplantation, Autologous, Treatment Outcome",

author = "X Thomas and S Suciu and B Rio and Giuseppe Leone and G Broccia and G Fillet and U Jehn and W Feremans and G Meloni and M Vignetti and {De Witte}, T and S. Amadori",

year = "2007",

language = "English",

volume = "92",

pages = "389--396",

journal = "Haematologica",

issn = "1592-8721",

publisher = "Ferrata Storti Foundation",

}

Thomas, X, Suciu, S, Rio, B, Leone, G, Broccia, G, Fillet, G, Jehn, U, Feremans, W, Meloni, G, Vignetti, M, De Witte, T & Amadori, S 2007, 'Autologous stem cell transplantation after complete remission and first consolidation in acute myeloid leukemia patients aged 61-70 years: results of the prospective EORTC-GIMEMA AML-13 study', Haematologica, vol. 92, pp. 389-396.

TY - JOUR

T1 - Autologous stem cell transplantation after complete remission and first consolidation in acute myeloid leukemia patients aged 61-70 years: results of the prospective EORTC-GIMEMA AML-13 study

AU - Thomas, X

AU - Suciu, S

AU - Rio, B

AU - Leone, Giuseppe

AU - Broccia, G

AU - Fillet, G

AU - Jehn, U

AU - Feremans, W

AU - Meloni, G

AU - Vignetti, M

AU - De Witte, T

AU - Amadori, S.

PY - 2007

Y1 - 2007

N2 - The optimal post-remission treatment for elderly patients with acute myeloid leukemia (AML) is presently unknown. Recent studies have reported the feasibility of autologous peripheral blood stem cell transplantation (PBSCT) in this population. We evaluate the outcome of this post-remission approach after complete remission (CR) and consolidation in elderly patients included in the EORTC-GIMEMA AML-13 trial.

AB - The optimal post-remission treatment for elderly patients with acute myeloid leukemia (AML) is presently unknown. Recent studies have reported the feasibility of autologous peripheral blood stem cell transplantation (PBSCT) in this population. We evaluate the outcome of this post-remission approach after complete remission (CR) and consolidation in elderly patients included in the EORTC-GIMEMA AML-13 trial.

KW - Administration, Oral

KW - Aged

KW - Aged, 80 and over

KW - Amsacrine

KW - Antineoplastic Combined Chemotherapy Protocols

KW - Carmustine

KW - Combined Modality Therapy

KW - Cytarabine

KW - Disease-Free Survival

KW - Etoposide

KW - Feasibility Studies

KW - Female

KW - Graft Survival

KW - Granulocyte Colony-Stimulating Factor

KW - Hematopoietic Stem Cell Transplantation

KW - Humans

KW - Idarubicin

KW - Infusions, Intravenous

KW - Injections, Subcutaneous

KW - Kaplan-Meier Estimate

KW - Leukemia, Myeloid

KW - Male

KW - Middle Aged

KW - Peripheral Blood Stem Cell Transplantation

KW - Prospective Studies

KW - Recombinant Proteins

KW - Survival Analysis

KW - Transplantation Conditioning

KW - Transplantation, Autologous

KW - Treatment Outcome

KW - Administration, Oral

KW - Aged

KW - Aged, 80 and over

KW - Amsacrine

KW - Antineoplastic Combined Chemotherapy Protocols

KW - Carmustine

KW - Combined Modality Therapy

KW - Cytarabine

KW - Disease-Free Survival

KW - Etoposide

KW - Feasibility Studies

KW - Female

KW - Graft Survival

KW - Granulocyte Colony-Stimulating Factor

KW - Hematopoietic Stem Cell Transplantation

KW - Humans

KW - Idarubicin

KW - Infusions, Intravenous

KW - Injections, Subcutaneous

KW - Kaplan-Meier Estimate

KW - Leukemia, Myeloid

KW - Male

KW - Middle Aged

KW - Peripheral Blood Stem Cell Transplantation

KW - Prospective Studies

KW - Recombinant Proteins

KW - Survival Analysis

KW - Transplantation Conditioning

KW - Transplantation, Autologous

KW - Treatment Outcome

UR - http://hdl.handle.net/10807/14646

M3 - Article

SN - 1592-8721

VL - 92

SP - 389

EP - 396

JO - Haematologica

JF - Haematologica

ER -

Autologous stem cell transplantation after complete remission and first consolidation in acute myeloid leukemia patients aged 61-70 years: results of the prospective EORTC-GIMEMA AML-13 study

Abstract

Keywords

Other files and links

Fingerprint

Cite this